Therapy News and Research

RSS

Mild electronic stimulation therapy to upper airway during sleep effective in reducing OSA

Results published in a new study in the Jan. 9 issue of the New England Journal of Medicine report that mild electronic stimulation therapy to the upper airway during sleep is effective in reducing obstructive sleep apnea (OSA).

9 Jan 2014

Study identifies risk factors linked with non-fatal overdose among HIV-infected Russians

Researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) have identified that injection frequency and taking anti-retroviral therapy for HIV are risk factors for nonfatal drug overdoses among Russians who are HIV positive and inject drugs.

9 Jan 2014

Cosmetic results after "lumpectomy" differ for African-American versus Caucasian women

As perceived by both patients and doctors, the cosmetic results after "lumpectomy" for breast cancer differ for African-American versus Caucasian women, suggests a pilot study in the Plastic and Reconstructive Surgery-Global Open-, the official open-access medical journal of the American Society of Plastic Surgeons (ASPS).

9 Jan 2014

Daily antibiotic use is effective for preventing recurrent urinary tract infections in women

While daily antibiotic use is the most effective method for preventing recurrent urinary tract infections in women, daily cranberry pills, daily estrogen therapy and monthly acupuncture treatments also have benefits that may be preferable for some patients, according to a new study by researchers at the Los Angeles Biomedical Research Institute.

9 Jan 2014

Implantation of sleep apnea device can lead to improvements for patients with OSA

Implantation of a sleep apnea device called Inspire- Upper Airway Stimulation therapy can lead to significant improvements for patients with obstructive sleep apnea, according to a study published today in the New England Journal of Medicine.

9 Jan 2014

Rexahn Pharmaceuticals initiates RX-3117 Phase Ib trial in cancer patients with solid tumors

Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company, announced today the initiation of a Phase Ib clinical trial to study the safety and efficacy of RX-3117 in cancer patients with solid tumors.

9 Jan 2014

Hebrew University research could lead to efficient and fast-acting antidepressant drugs

The World health Organization calls depression "the leading cause of disability worldwide," causing more years of disability than cancer, HIV/AIDS, and cardiovascular and respiratory diseases combined.

8 Jan 2014

Plasma thermogram can serve as an indicator of cervical cancer

Researchers at the University of Louisville have confirmed that using the heat profile from a person's blood, called a plasma thermogram, can serve as an indicator for the presence or absence of cervical cancer, including the stage of cancer.

8 Jan 2014

C. parvum and cryptosporidiosis: an interview with Dr. Momar Ndao, McGill University

Cryptosporidium parvum is one of the most common enteropathogens to affect humans in the world. The protozoan parasite causes a gut infection referred to as cryptosporidiosis.

8 Jan 2014

Immunocore, MedImmune sign oncology research collaboration and licensing agreement

Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, today announced that it has entered into an oncology research collaboration and licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca. Both companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer technology.

8 Jan 2014

Emmaus completes all patient visits for Phase 3 trial of L-glutamine for treatment of sickle cell disease

Emmaus Medical, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of innovative and cost-effective treatments and therapies primarily for rare and orphan diseases, today announced it has completed all patient visits for its Phase 3 clinical trial for the treatment of sickle cell disease. Emmaus expects top-line data from the Phase 3 clinical trial to be available in the first quarter of 2014.

8 Jan 2014

No added benefit from aflibercept, shows study

For the third time in one year, the German Institute for Quality and Efficiency in Health Care (IQWiG) dealt with the drug aflibercept. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the Institute now examined whether aflibercept (trade name: Eylea) offers an added benefit over the appropriate comparator therapy in visual impairment due to macular oedema following occlusion of the central retinal vein.

8 Jan 2014

Experts gather to bring mindfulness in youths

Experts in the field of mindfulness will gather in San Diego from Feb. 7-9 to share the latest advancements in education, clinical care and research as it applies to the healthy development of youth through the application of meditation.

8 Jan 2014

Quick tips to avoid carbon monoxide poisoning

Temperatures in the next few days are predicted to be the coldest of the winter so far, and people using space heaters to get some extra warmth into their living and working spaces need to be aware of a potential "silent killer" inside their homes and offices — carbon monoxide (CO).

8 Jan 2014

Apitope-led consortium awarded FP7 Health Innovation funding to develop Graves' disease vaccine

Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announces that the consortium, led by Apitope, which includes GSK Vaccines, Quintiles and KWS Biotest Limited, has been awarded prestigious Framework Programme 7 Health Innovation funding by the European Commission to develop its Graves' disease therapeutic vaccine, including a Phase I first-in-man study in Graves' disease patients.

8 Jan 2014

Study raises hopes for new drugs to treat brain disorders associated with neurotransmitter imbalance

Although drugs have been developed that inhibit the imbalance of neurotransmitters in the brain - a condition which causes many brain disorders and nervous system diseases - the exact understanding of the mechanism by which these drugs work has not yet been fully understood.

8 Jan 2014

IDMC recommends early stopping of Phase 3 study of ibrutinib in treatment of CLL/SLL

Janssen-Cilag International NV today announced the early stopping of PCYC-1112-CA, the Phase 3 study of ibrutinib in the treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, based on the recommendation of an Independent Data Monitoring Committee, which concluded that the study showed a significant difference in progression-free survival as compared to the control, the primary endpoint of the study.

8 Jan 2014

OASIS receives research award from MJFF to develop saliva-based, rapid test for Parkinson's detection, diagnosis

Oasis Diagnostics Corporation is the recipient of a research award from The Michael J. Fox Foundation for Parkinson's Research to validate OASIS' development of a non-invasive, saliva-based, rapid test for Parkinson's disease detection and diagnosis.

8 Jan 2014

Cancer Treatment Centers of America recognized with Clinical Nutrition Team of Distinction Award

Cancer Treatment Centers of America has been recognized by the American Society for Parenteral and Enteral Nutrition with the organization's "Clinical Nutrition Team of Distinction Award". Members of the CTCA professional staff will be honored by A.S.P.E.N at its Clinical Nutrition Week Conference in Savannah, GA this January 2014. This award is presented to multi-discipline clinical teams that exemplify excellence in interdisciplinary clinical nutrition practice in compliance with A.S.P.E.N. standards, guidelines and values.

8 Jan 2014

Study: Combined medications may improve smoking cessation than single drug therapy

Among cigarette smokers, combining the smoking cessation medications varenicline and bupropion, compared with varenicline alone, resulted in higher smoking abstinence rates for one outcome but not the other at three and six months; rates were similar at one year, according to a Mayo Clinic study published this month in JAMA.

8 Jan 2014

Therapy News and Research

Mild electronic stimulation therapy to upper airway during sleep effective in reducing OSA

Study identifies risk factors linked with non-fatal overdose among HIV-infected Russians

Cosmetic results after "lumpectomy" differ for African-American versus Caucasian women

Daily antibiotic use is effective for preventing recurrent urinary tract infections in women

Implantation of sleep apnea device can lead to improvements for patients with OSA

Rexahn Pharmaceuticals initiates RX-3117 Phase Ib trial in cancer patients with solid tumors

Hebrew University research could lead to efficient and fast-acting antidepressant drugs

Plasma thermogram can serve as an indicator of cervical cancer

C. parvum and cryptosporidiosis: an interview with Dr. Momar Ndao, McGill University

Immunocore, MedImmune sign oncology research collaboration and licensing agreement

Emmaus completes all patient visits for Phase 3 trial of L-glutamine for treatment of sickle cell disease

No added benefit from aflibercept, shows study

Experts gather to bring mindfulness in youths

Quick tips to avoid carbon monoxide poisoning

Apitope-led consortium awarded FP7 Health Innovation funding to develop Graves' disease vaccine

Study raises hopes for new drugs to treat brain disorders associated with neurotransmitter imbalance

IDMC recommends early stopping of Phase 3 study of ibrutinib in treatment of CLL/SLL

OASIS receives research award from MJFF to develop saliva-based, rapid test for Parkinson's detection, diagnosis

Cancer Treatment Centers of America recognized with Clinical Nutrition Team of Distinction Award

Study: Combined medications may improve smoking cessation than single drug therapy

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News